Last reviewed · How we verify

NCT04125940

Blood Nitrate/Nitrite Concentrations Following Acute Ingestion of Resync in Men and Women

Completed NA Last updated 28 April 2021
What this trial tests

NA trial testing Resync in Healthy in 20 participants. Completed in 30 December 2019.

Timeline
14 October 2019
Primary endpoint
30 December 2019
30 December 2019

Quick facts

Lead sponsorUniversity of Memphis
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposebasic science
Enrollment20
Start date14 October 2019
Primary completion30 December 2019
Estimated completion30 December 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Memphis

Who can join

Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates acute ingestion of the dietary supplement Resync on blood nitrate/nitrite concentrations in a sample of men and women. This will be a crossover trial in which participants take all 4 conditions: 1) 7.5g Resync, 2) 15g Resync, 3) 20g Resync+collagen, 4) placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other University of Memphis trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04125940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing